•  
  •  
 

Authors

Syed Osman Ahmed, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Riad El Fakih, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi ArabiaFollow
Alaa Elhaddad, National Cancer Institute, Cairo University, Cairo, Egypt
Amir Ali Hamidieh, Tehran University of Medical Sciences, Hematology, Oncology & SCT Research Ctr., Tehran, Iran
Abdulghani Altbakhi, King Hussein Cancer Center, Amman, Jordan
Qamar-Un-Nisa Chaudhry, Armed Forces Bone Marrow Transplant Centre/National Institute of Blood and Marrow Transplant, Rawalpindi, Pakistan
Ali Bazarbachi, Department of Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon
Salman Adil, Department of Oncology, the Aga Khan University, Karachi, Pakistan
Murtadha Al-khabori, Sultan Qaboos University, Muscat, Oman
Tarek Ben Othman, Center National de Greffe de Moelle Osseuse de Tunis, Tunis, Tunisia
Javid Gaziev, National Center for Cancer Care & Research Hamad Medical Corporation, Doha, Qatar
Mohamad Khalaf, Maadi Armed Forces Medical Compound Hematology/Oncology Hospital, Cairo, Egypt
Salem Alshammeri, Faculty of Medicine, Kuwait University, Jabriya, Kuwait
Sultan Alotaibi, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Mohammed Alshahrani, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Mohamed Amine Bekadja, University Hospital Establishment 1st Nov, Oran, Algeria
Ahmad Ibrahim, Makassed General Hospital and Middle East Institute of Health Beirut, Lebanon
Adel Mohammed Al-Wahadneh, Department of Pediatrics, Queen Rani Children’s Hospital, Amman, Jordan
Muna Altarshi, The Royal Hospital, Muscat, Oman
Ahmad Alsaeed, King Abdulaziz Medical City, Ministry of National Guard, Jeddah, Saudi Arabia
Abdellah Madani, Hematology, Pediatric Oncology, Ibn Rochd University Hospital, University of Hassan II, Casablanca, Morocco
Miguel Abboud, Department of Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon
Husam Abujazar, King Hussein Cancer Center, Amman, Jordan
Mohamad Bakr, National Center for Cancer Care & Research Hamad Medical Corporation, Doha, Qatar
Ibraheem Abosoudah
Jean El Cheikh, Department of Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon
Ahlam Almasari
Feras Alfraih, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Helen Baldomero
Hassan Elsolh, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Dietger Niederwieser
Naeem Chaudhri, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Mahmoud Aljurf, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Abstract

The World Health Organization-designated Eastern Mediterranean region (EMRO) consists of 22 countries in North Africa and Western Asia with a collective population of over 679 million. The area comprises some of the wealthiest countries per capita income and some of the poorest. The population structure is also unique and contrasts with western countries, with a much younger population. The region sits in the heart of the thalassemia belt. Many countries have a significant prevalence of sickle cell disease, and cancer is on the rise in the region. Therefore, the strategic priorities for the growth and development of hematopoietic stem cell transplantation (HSCT) differ from country to country based on resources, healthcare challenges, and prevalent infrastructure. Thirty-one reporting teams to the Eastern Mediterranean Blood and Marrow Transplantation Group have active HSCT programs in 12 countries; allogeneic transplants outnumber autologous transplants, and the proportion of allotransplants for nonmalignant conditions is higher in the EMRO region than in Western Europe and North America. The vast majority (99%) of allotransplants are from matched related donors. Matched unrelated donors and other alternate donor transplants are underutilized. The chance of finding a matched related donor for allografts is higher, with a significant chance of finding matched donors among non-sibling related donors. Reasons for relatively lower rates of transplants compared with other countries are multifactorial. Capacity building, development of newer centers, innovative funding, and better utilization of information technology are required to make transplantation as an accessible modality to more patients. Cost-effectiveness and cost-containment, regulation, and ensuring quality will all be priorities in planning HSCT development in the region.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

COinS